Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis

Abstract

Programmed cell death 1 (PDCD1 or PD1) polymorphisms have been inconsistently reported to be associated with systemic lupus erythematosus (SLE). The aim of this study was to explore whether the PDCD1 polymorphisms confer a susceptibility to SLE and lupus nephritis (LN). We conducted a meta-analysis on the association of PDCD1 polymorphisms with SLE in overall and specific ethnic populations. A total of 15 separate comparisons were included in this meta-analysis consisting of nine Europeans, two Latin Americans, two Africans, one Asian and one unknown participant. In subgroup analysis, the PD1.3A allele was significantly associated with SLE in Latin Americans (OR = 3.073, 95% CI = 1.416-6.461, P = 0.003), but not in patients of European and African decent. The PD1.3A allele was a risk factor for LN in European descendants (OR = 2.207, 95% CI = 1.488-3.467, P < 0.001). The PD1.5C allele was a risk factor for SLE in Europeans (OR = 1.297, 95% CI = 1.024-1.643, P = 0.031). In conclusion, this meta-analysis demonstrated an association of the PD1.3A allele with LN in European and SLE in Latin-American populations. Furthermore, the PD1.5C allele was associated with SLE susceptibility in Europeans.

The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis

“…Possible explanations for controversial results include clinical heterogeneity, ethnic differences, real genetic heterogeneity, and small sample sizes. Meta-analysis provides a useful means of analyzing inconsistent results because it increases sample size, and thus statistical power [18,26,27]. Accordingly, in the present study, because of the inconsistent results published on relationships between IL-6 polymorphisms and RA, we utilized meta-analysis to clarify associations.…”

Correlation between circulating osteopontin level in systemic lupus erythematosus and disease activity and associations between osteopontin polymorphisms and disease susceptibility: A meta-analysis

“…In order to overcome the limitations of individual studies and resolve inconsistencies, we performed this meta-analysis. [17][18][19] The aim of this meta-analysis was to systematically review the evidence on serum/plasma OPN levels in SLE patients compared to those in healthy controls and the correlation of OPN with disease activity, as well as determine whether OPN polymorphisms are associated with SLE susceptibility.…”

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

“…PDCD1 is expressed by activated T cells, B cells and myeloid cells and down-regulates B-and T-cell responses, making it a necessary negative regulator of self-reactivity. Many studies have shown the contribution of PDCD1 polymorphisms to SLE susceptibility in certain ethnic cohorts [52][53][54], and some studies have shown an association of certain PD gene alleles with lupus nephritis [55][56][57]. We propose that we could better stratify SLE patients by adding PD1 (CD279) to the cell-capture array.…”